Custom Search

News

Tuesday 01 July 2003

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).

By: Cooper HL, Healy E, Theaker JM, Friedmann PS.

Clin Exp Dermatol 2003 Jul;28(4):366-8

We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.

Use of this site is subject to the following terms of use